Menu
Recruiting NCT05060614

Analyses of Cerebrospinalfluid in Patients With Delirium

Observational Delirium

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Hip fracture surgery.
Who it may be relevant to
Registry conditions: Delirium. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Norway
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

MOLECULAR BIOMARKERS IN DELIRIUM AND DEMENTIA

Overview

The current project aims to measure biomarkers in the cerebrospinalfluid (CSF) and serum samples from patients with delirium. We hope to uncover new insights into the pathophysiology of delirium and explore its link to dementia.

Detailed description

Delirium is a common and serious complication to acute illness, and is characterized by acute disturbances in attention, awareness, and cognition. Dementia is a major risk factor of delirium, and delirium increases the risk of dementia progression and development. As the conditions share both clinical and epidemiological features, some researchers suggest that also pathophysiological links are shared. Understanding delirium pathophysiology, which is poorly understood, may thus help elucidate early molecular mechanisms in dementia.

This study aims to to increase our understanding of the pathophysiology of delirium and molecular links between delirium and dementia, by exploring cerebrospinal fluid (CSF) biomarkers.

Interventions

  • Procedure Hip fracture surgery
    Hip fracture surgery

Primary outcome measures

  • Delirium [Time frame: Daily during hospital stay (pre-/and postoperatively) until 5 days after surgery (or discharge)]
Secondary outcome measures (1)
  • Dementia [Time frame: Cognitive changes the first 48 months after inclusion]

Eligibility criteria

Inclusion criteria

  • Patients with acute hip fracture

Exclusion criteria

  • Moribund patients.
  • Lack of consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

Norway · 1 center
  • Leiv Otto Watne — Oslo

Identifiers

NCT: NCT05060614 · 2016/1368

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗